STOCK TITAN

Baxter International (BAX) Stock Price, News & Analysis

BAX NYSE
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
14 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
-16% close of February 12, 2026
1-year change
+45.8% closing prices, November 20, 2025 to November 20, 2026
1-month change
+3.6% closing prices, October 20, 2026 to November 20, 2026

Company Description

Baxter International Inc. (NYSE: BAX) is a global medtech company in the surgical and medical instrument manufacturing industry. According to company statements, Baxter focuses on essential solutions in the hospital, physician’s office and other sites of care. Its portfolio spans connected care technologies, medical devices and advanced injectable technologies that are used by healthcare providers and patients across multiple care settings.

The company describes its enduring mission as to Save and Sustain Lives, and notes that for nearly a century customers have relied on Baxter as a vital and trusted partner. Baxter highlights that millions of patients and healthcare providers depend on its portfolio of connected solutions, medical devices and injectable therapies each day. The company’s common stock is listed on the New York Stock Exchange under the symbol BAX, and it has also issued global notes that trade on the NYSE.

Business focus and product areas

Based on available information, Baxter’s business centers on technologies and products that support direct patient care and clinical workflows. From its legacy operations, Baxter offers injectable therapies for use in care settings, including IV pumps, administration sets and solutions, nutritional products, and surgical sealants and hemostatic agents. The company has also described itself as an innovative leader in infusion therapies and technologies, with smart infusion pumps and related safety software designed to support controlled administration of fluids such as pharmaceutical drugs, blood and blood products.

Baxter expanded its hospital-focused offerings by acquiring Hillrom, which added equipment such as hospital beds, operating room equipment and patient monitoring tools. In more recent communications, Baxter emphasizes a portfolio of smart beds, surfaces and connected care solutions for medical-surgical units and intensive care units, as well as connected infusion systems that integrate with electronic medical records (EMRs). Baxter has also disclosed that it sold its kidney care tools business, indicating a strategic shift in its portfolio.

Connected care and digital integration

Several Baxter announcements underscore the company’s emphasis on connected care technologies. Baxter reports that its solutions can integrate with hospital EMRs to enable features such as auto-programming of infusions and dose-error reduction systems. In collaboration with The University of Texas Medical Branch, Baxter presented real-world data on its Spectrum IQ large volume infusion pumps, showing that EMR integration was associated with reductions in certain safety alerts, time to program infusions and time to resolve alerts. These capabilities are described as supporting patient safety, clinician productivity and programming compliance.

Baxter also highlights connected features in its smart bed and stretcher offerings. For example, the Dynamo Series stretcher is described as having optional wireless connectivity to deliver select clinical safety and patient data to the EMR, and integration with Baxter’s Voalte Nurse Call and other systems to send real-time notifications to care teams. Technologies such as the SafeView+ system and bed exit alarms are presented as tools to help anticipate risk and reduce patient falls, while also easing the cognitive burden on care teams.

Examples of Baxter solutions

Within its infusion therapy portfolio, Baxter describes the Spectrum IQ Infusion System with Dose IQ Safety Software as intended for controlled administration of fluids via routes such as IV, arterial, subcutaneous or epidural. The system is designed to be used with compatible IV administration sets and medications, and to reduce operator interaction through guided programming and automation of infusion parameter programming and documentation. The company states that these automation features are intended to reduce pump programming errors.

In the area of patient handling and monitoring, Baxter has announced the Dynamo Series smart stretcher, intended for emergency departments, perioperative environments and patient transport services. The stretcher is described as designed to minimize the need for patient transfers by enabling a range of procedures to be performed in-stretcher, with integrated stirrups and a full electric suite for powered drive and positioning. Baxter notes that the Dynamo Series includes features aimed at enhancing patient safety and comfort, such as one-touch positioning controls, the ability to convert to a true chair position and a wide care surface.

Partnerships and care delivery initiatives

Baxter’s communications also reference partnerships that focus on care delivery and nursing workflows. A multi-year strategic partnership with MUSC Health is described as aiming to enhance patient care through integrated connected care technologies. Objectives include standardizing and simplifying bedside technologies, reducing documentation time, streamlining communication, improving nurse satisfaction and retention, and using real-time insights and advanced monitoring to support quality and safety outcomes. Baxter characterizes these efforts as aligned with its vision to redefine healthcare delivery and improve the experiences of care teams through connected technologies and services.

Capital structure and financing activities

SEC filings indicate that Baxter is incorporated in Delaware and has securities registered under Section 12(b) of the Securities Exchange Act of 1934, including its common stock and certain global notes. The company has undertaken various financing and liability management transactions, such as issuing senior notes due 2029, 2030 and 2035 and conducting tender offers for existing senior unsecured notes due 2026 and 2027. Baxter has also amended its credit agreements and repaid a term loan facility using proceeds from new notes. These activities are described in detail in Baxter’s Form 8-K filings and related offering documents.

Corporate responsibility and philanthropy

Through the Baxter Foundation, described as the philanthropic arm of Baxter International Inc., the company supports initiatives that align with its mission to Save and Sustain Lives. The Foundation focuses on increasing access to healthcare for underserved populations, developing the next generation of innovators in healthcare and creating positive, long-lasting community impact. One example is a multi-year grant to Northwestern University’s School of Education and Social Policy to support the Baxter Center for Science Education, which provides STEM programs, educator professional development, classroom lab resources and student experiences in the Chicagoland area.

Stock information and investor focus

Baxter’s common stock trades on the New York Stock Exchange under the symbol BAX. The company has communicated decisions regarding its dividend policy, including a reduction in the quarterly dividend to reallocate cash flow toward deleveraging. Baxter’s SEC filings and press releases also describe its use of tender offers and new debt issuance as part of broader refinancing and capital allocation plans. Investors can review Baxter’s Form 8-K filings and other SEC documents for details on these transactions, credit agreements and governance developments.

Summary

According to its public statements, Baxter International Inc. is a global medtech company that provides connected solutions, medical devices and advanced injectable technologies across hospitals, physician offices and other care sites. Its offerings include infusion therapies and smart pumps, smart beds and stretchers, and other equipment and technologies that support patient safety, clinician workflows and connected care. The company complements its commercial activities with partnerships focused on care delivery and nursing practice, as well as philanthropic initiatives in healthcare access and STEM education.

Stock Performance

$25.43
+0.16%
+0.04
After hoursChange vs the $25.39 closeLast updated: at
+45.8%
Performance 1 year
$13.2B
517.3M
Shares outstanding As of October 22, 2026.

Baxter International (BAX) closed at $25.39 on November 20, 2026. Over the past 12 months, the price has gained 45.8%.

See what a $1,000 investment in BAX would be worth today

Average down calculator for BAX

BAX Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Baxter International has 10 recent news articles. Of the recent coverage, 7 articles coincided with positive price movement and 3 with negative movement. Key topics include conferences, earnings date. View all BAX news →

Financial Highlights

Baxter International generated $11.2B in revenue in FY2025, retaining a 30.0% gross margin, operating income reached -$308.0M (-2.7% operating margin), and net income was -$957.0M, reflecting a -8.5% net profit margin. Diluted earnings per share stood at -$1.87. The company generated $845.0M in operating cash flow. The current ratio was 2.31, measuring current assets divided by current liabilities.

$11.2B
Revenue (FY2025)
-$957.0M
Net Income (FY2025)
$845.0M
Operating Cash Flow

Upcoming Events

YEAR
2040
2040 Operations

100% renewable electricity target

Target: 100% renewable electricity by 2040. Baxter pledges company-wide renewable energy transition and sourcing goal.
YEAR
2050
2050 Operations

Net-zero Scope 1 & 2 target

Target: net-zero Scope 1 and 2 greenhouse gas emissions by 2050. Long-term operational ESG milestone for Baxter.

Baxter International has 2 upcoming scheduled events. The next event, "100% renewable electricity target", is expected in 2040. Investors can track these dates to stay informed about potential catalysts that may affect the BAX stock price.

Short Interest History

Last 12 Months

Short interest in Baxter International (BAX) currently stands at 23.7 million shares, down 0.4% from the previous reporting period, representing 4.6% of the float. Since November 2025, short interest has decreased by 28.6%.

Days to Cover History

Last 12 Months

Days to cover for Baxter International (BAX) currently stands at 3.0 days, down 28.4% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 31%. Across the settlements charted above, it has ranged from 3.0 to 6.5 days.

BAX Company Profile & Sector Positioning

Baxter International (BAX) operates in the Medical Instruments & Supplies industry within the broader Healthcare sector and is listed on the NYSE. Among dividend-paying stocks, BAX ranks #2,024 by dividend yield.

Investors comparing BAX often look at related companies in the same sector, including Solventum Corporation (SOLV), The Cooper Companies, Inc. (COO), Align Technology Inc (ALGN), Avantor, Inc. (AVTR), and Repligen Corp (RGEN). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate BAX's relative position within its industry.

Frequently Asked Questions

The current stock price of Baxter International (BAX) is $25.43 in after-hours trading as of November 20, 2026.

The market cap of Baxter International (BAX) is approximately $13.2B. Learn more about what market capitalization means .

The FY2025 revenue of Baxter International (BAX) is $11.2B, from its most recent completed fiscal year.

The FY2025 net income of Baxter International (BAX) is -$957.0M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Baxter International (BAX) is -$1.87 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Baxter International (BAX) is $845.0M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Baxter International (BAX) is -8.5% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Baxter International (BAX) is -2.7% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Baxter International (BAX) is 30.0% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Baxter International (BAX), current assets divided by current liabilities, was 2.31 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Baxter International (BAX) is $3.4B for FY2025, its most recent completed fiscal year.

The operating income of Baxter International (BAX) is -$308.0M for FY2025, its most recent completed fiscal year. Learn about operating income.

Baxter International Inc. describes itself as a global medtech company providing essential solutions in the hospital, physician’s office and other sites of care. Its portfolio includes connected care technologies, medical devices and advanced injectable technologies that support patient care and clinical workflows.

Baxter operates in the surgical and medical instrument manufacturing industry. Company materials also refer to Baxter as a global medtech leader with offerings in infusion therapies and technologies, smart beds, surfaces and other hospital-focused equipment.

Baxter states that its enduring mission is to Save and Sustain Lives. The company notes that for nearly a century customers have relied on it as a vital and trusted partner, and that millions of patients and healthcare providers depend on its portfolio of connected solutions, medical devices and advanced injectable technologies.

According to company disclosures, Baxter’s portfolio includes injectable therapies, IV pumps, administration sets and solutions, nutritional products, surgical sealants and hemostatic agents, smart infusion pumps with safety software, smart beds and surfaces, stretchers such as the Dynamo Series, and connected care technologies that can integrate with electronic medical records and nurse call systems.

Baxter describes the Spectrum IQ Infusion System with Dose IQ Safety Software as intended for the controlled administration of fluids, including pharmaceutical drugs, blood and blood products, via routes such as IV, arterial, subcutaneous or epidural. It is designed to work with compatible IV administration sets and medications and to reduce operator interaction through guided programming and automation of infusion parameter programming and documentation.

The Dynamo Series is a smart stretcher announced by Baxter for use in emergency departments, perioperative environments and patient transport services. Baxter states that it is designed to reduce the need for patient transfers, support a range of procedures in-stretcher, incorporate advanced technologies to help prevent patient falls and improve safety, and offer features to enhance patient comfort and autonomy.

Baxter reports that its connected care technologies can integrate with hospital electronic medical records and systems such as Voalte Nurse Call. These integrations support features like auto-programming of infusions, delivery of clinical safety and patient data to the EMR, and real-time notifications to care teams, with the goal of supporting patient safety, reducing manual tasks and easing clinicians’ cognitive burden.

The Baxter Foundation is described as the philanthropic arm of Baxter International Inc. It helps advance Baxter’s mission by partnering with organizations to increase access to healthcare for underserved populations, develop the next generation of innovators in healthcare and create positive, long-lasting community impact. One example is funding for the Baxter Center for Science Education to support STEM programs for students and teachers in the Chicagoland area.

Baxter’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the New York Stock Exchange under the ticker symbol BAX, as indicated in the company’s Form 8-K filings.

Company information notes that Baxter expanded its hospital-focused offerings through the acquisition of Hillrom, adding hospital beds, operating room equipment and patient monitoring tools. Baxter has also disclosed the sale of its kidney care tools business, reflecting changes in its portfolio focus.